Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesGenetics
You have accessRestricted Access

Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis: Phenotype–Genotype Correlation and Outcome in 32 Patients with CLDN16 or CLDN19 Mutations

Astrid Godron, Jérôme Harambat, Valérie Boccio, Anne Mensire, Adrien May, Claire Rigothier, Lionel Couzi, Benoit Barrou, Michel Godin, Dominique Chauveau, Stanislas Faguer, Marion Vallet, Pierre Cochat, Philippe Eckart, Geneviève Guest, Vincent Guigonis, Pascal Houillier, Anne Blanchard, Xavier Jeunemaitre and Rosa Vargas-Poussou
CJASN May 2012, 7 (5) 801-809; DOI: https://doi.org/10.2215/CJN.12841211
Astrid Godron
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérôme Harambat
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valérie Boccio
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Mensire
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrien May
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Rigothier
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lionel Couzi
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benoit Barrou
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Godin
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Chauveau
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanislas Faguer
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Vallet
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Cochat
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Eckart
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geneviève Guest
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Guigonis
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Houillier
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Blanchard
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Jeunemaitre
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Vargas-Poussou
Due to the number of contributing authors, the affiliations are provided in the .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Summary

Background and objectives Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is a rare autosomal recessive renal tubular disease. It is caused by mutations in CLDN16 and CLDN19, encoding claudin-16 and -19, respectively. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is usually complicated by progressive CKD. The objectives of this study were to describe the clinical and genetic features of familial hypomagnesemia with hypercalciuria and nephrocalcinosis and analyze phenotype–genotype associations in patients with CLDN16 or CLDN19 mutations.

Design, setting, participants, & measurements Data from 32 genetically confirmed patients (9 patients with CLDN16 and 23 patients with CLDN19 mutations) from 26 unrelated families were retrospectively reviewed.

Results Diagnosis was based on clinical criteria at a median age of 9.5 years and confirmed by genetic testing at a median age of 15.5 years. In total, 13 CLDN16 or CLDN19 mutations were identified, including 8 novel mutations. A founder effect was detected for the recurrent CLDN16 p.Ala139Val mutation in North African families and the CLDN19 p.Gly20Asp mutation in Spanish and French families. CKD was more frequently observed in patients with CLDN19 mutations: survival without CKD or ESRD was 56% at 20 years of age in CLDN19 versus 100% in CLDN16 mutations (log rank P<0.01). Ocular abnormalities were observed in 91% of patients with CLDN19 mutations and none of the patients with CLDN16 mutations (P<0.01). Treatments seem to have no effect on hypercalciuria and CKD progression.

Conclusions Patients with CLDN19 mutations may display more severe renal impairment than patients with CLDN16 mutations. Ocular abnormalities were observed only in patients with CLDN19 mutations.

Introduction

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC; Online Mendelian Inheritance in Man 248250) is a rare autosomal recessive disease first described as Michelis-Castrillo syndrome (1). Only 87 patients (51 families) have been described to date in international publications (2,3). It is caused by mutations in the CLDN16 and CLDN19 genes, encoding claudin-16 and -19 (4,5). These two proteins are expressed in the tight junction of the thick ascending limb (TAL) of Henle’s loop and are involved in the paracellular reabsorption of calcium and magnesium (6). Claudin proteins are expressed in various tissues, and claudin-19 has also been detected in the retinal epithelium (7). Mutations of these genes are responsible for urinary loss of magnesium and calcium, resulting in hypomagnesemia, hypercalciuria, nephrolithiasis, and nephrocalcinosis. FHHNC patients suffer from progressive CKD, which may lead to ESRD in the teens or 20s (2). No difference in renal phenotype between patients with mutations in these two genes has yet been described. By contrast, severe ocular involvement (macular coloboma, pigmentary retinitis, nystagmus, or visual loss) has been described in CLDN19 patients, whereas only mild nonspecific ocular involvement (myopia, astigmatism, hypermetropia, or strabismus) has been reported in some CLDN16 patients (3,6,8).

In this study, we aimed to describe the clinical features, molecular genetics, and disease outcome, focusing on renal progression, in a cohort of 32 patients with mutations in the CLDN16 or CLDN19 genes.

Materials and Methods

Patients

Clinical and biochemical data for 32 genetically defined FHHNC patients from 26 families were studied retrospectively. Data collected included demographic, genetic, clinical, and biologic data obtained at diagnosis and during follow-up. Estimated GFR (eGFR) was calculated with the updated Schwartz formula for children and the Modification of Diet in Renal Disease formula for adults (9,10).

Genetic Studies

Detection of Point Mutations.

Genomic DNA was extracted by standard methods from peripheral blood samples after written informed consent had been obtained from the patients or their parents. Mutation analysis was performed based on PCR amplification followed by sequencing as described (11,12) (primers available on request) on an ABI Prism 3730XL DNA Analyzer (Perkin Elmer Applied Biosystems, Foster City, CA). Mutations were interpreted, and the degree of amino acid conservation between orthologs and Grantham distance was assessed with Alamut v.2.0 software (Interactive Biosoftware, Rouen, France; http://www.interactivebiosoftware.com/). Complementary analyses were performed with SIFT (http://www.Blocks.fhcrc.org/sift/SIFT.html), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph/), MutationTaster (http://www.mutationtaster.org/), SNPs&Go (http://snps-and-go.biocomp.unibo.it/snps-and-go/), and MutPred (http://mutpred.mutdb.org/) algorithms.

Quantitative Multiplex PCR for Short Fluorescent Fragments.

We adapted the quantitative multiplex PCR for short fluorescent fragments (QMPSF) method (13) for the detection of large rearrangements of the CLDN19 gene for patients with homozygous mutations and no history of consanguinity for whom parental DNA was not available. Each multiplex PCR included a set of specific primers for each exon (primers available on request), and a fragment from the hydroxymethylbilane synthase gene was the internal control. The forward primer of each pair was 5′ end-labeled with 6-FAM fluorochrome. Amplified DNA fragments were separated by capillary electrophoresis on an ABI Prism 3730XL DNA Analyzer (Applied Biosystems, Foster City, CA). Data were analyzed with GeneMapper Software version 4.0 (Applied Biosystems, Foster City, CA). Each QMPSF reaction was validated with positive and negative reference DNAs.

Haplotype Analysis.

Haplotype analysis was carried out in families harboring two recurrent mutations (p.Ala139Val for CLDN16 and p.Gly20Asp for CLDN19) to determine whether these families were descended from a common ancestor. Polymorphic microsatellite markers flanking each locus were amplified by PCR, subjected to automated capillary electrophoresis, and sized with GeneMapper v 4.0 software. We used the markers D3S1294, D3S1314, and D3S1288 (GenBank accession numbers Z16944, Z17168, and Z16855) for CLDN16 with the following genetic map: D3S1294, 0.4 cM; D3S1314, 0.01 cM; CLDN16, 0.1 cM; D3S1288. For CLDN19, we used markers D1S463, D1S193, and D1S447 (GenBank accession numbers Z23403, Z16490.1, and Z23291.1) with the following genetic map: D1S463, 0.5 cM; D1S193, 0.18 cM; CLDN 19, 0.75 cM; D1S447.

Statistical Analyses

Results were expressed as median and interquartile range (IQR) for continuous variables and percentages for categorical variables. Comparative analyses of qualitative variables were carried out with the chi-squared or Fisher exact test, whereas comparisons of quantitative variables were based on t or Wilcoxon test in cases of skewed distribution. CKD-free survival was estimated from birth with a time to failure Kaplan–Meier method. The endpoint was the first measurement of eGFR below 60 ml/min per 1.73 m2. Data were censored at the last available measurement. ESRD-free survival was also estimated. Log rank tests were used to compare subgroups. A P value<0.05 was considered statistically significant. Statistical analyses were performed with SAS 9.1 (SAS Institute, Cary, NC).

Results

Demographics

Thirty-two patients (14 male and 18 female) from 26 unrelated families were included. Seventeen of the families were Caucasian, seven were from North Africa, one was from sub-Saharan Africa, and one was from the French West Indies. One family included three affected siblings (family 12), and four families included two affected siblings (families 2, 9, 11, and 23).

Genetic Investigations

Molecular studies revealed CLDN16 mutations in the probands of eight families and CLDN19 mutations in the probands of 18 families (Tables 1 and 2). Patients 1, 2, 5, 17, and 18 have been described elsewhere (11,12,14).

View this table:
  • View inline
  • View popup
Table 1.

Mutations of the CLDN16 gene in familial hypomagnesemia, hypercalciuria, and nephrocalcinosis patients

View this table:
  • View inline
  • View popup
Table 2.

Mutations of the CLDN19 gene in familial hypomagnesemia, hypercalciuria, and nephrocalcinosis patients

CLDN16 Mutations.

Six different mutations of the CLDN16 gene were detected (five missense and one nonsense) (Table 1). Three of the missense mutations (p.Cys80Tyr, pLys183Glu, and p.Gly233Arg) had never been described. They were not found in 100 control chromosomes and were predicted to be deleterious by at least three of the in silico methods (Supplemental Table 1). All patients were homozygous for the detected mutation. Patients from three North African families harbored the same missense mutation (p.Ala139Val), and an analysis of microsatellite markers showed that they shared the same haplotype at the disease locus (Figure 1), suggesting a common ancestor.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Haplotypes of three North African families carrying the p.Ala139Val mutation. Families 2 and 5 were consanguineous; family 6 has no history of consanguinity, but the mutation was homozygous.

CLDN19 Mutations.

Seven different mutations of the CLDN19 gene were detected (three missense, two nonsense, one frame shift, and one large deletion) (Table 2). Only two of the missense mutations have been described before. The probands of two families were compound heterozygous. All the other patients were homozygous, although most had no history of consanguinity. The known mutation, p.Gly20Asp, was particularly frequent in our group of patients (homozygous in 13 probands and heterozygous and associated with a second mutation in 2 probands). The parents in families 10, 20, and 26 were heterozygous, whereas QMPSF ruled out heterozygous deletions in the other families. The p.Gly20Asp mutation has been described as a founder effect in Spanish families. These results and the detection of this mutation in 2 Spanish and 12 Southwest France probands are consistent with such a founder effect. An analysis of microsatellite markers also provided support for this hypothesis: most of the patients carrying this mutation had the same haplotype at the disease locus or at least at the closest D1S193 marker (Figure 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Haplotypes of 14 nonconsanguineous French and Spanish families carrying the p.Gly20Asp mutation. In probands of families 17 and 25, this mutation was heterozygous and associated with a second mutation; the probands of all the other families were homozygous.

Clinical and Biologic Presentation at Diagnosis

In this cohort of 32 patients, a family history of FHHNC or other renal symptoms related to the disease (i.e., renal failure, lithiasis, or tubulopathy) was present in 50% of cases. The main symptoms at diagnosis included urinary tract infections, nephrolithiasis, nephrocalcinosis, and polyuria/polydipsia (Table 3). Age at onset ranged from 1 to 14 years, with a median age at onset of 7 years. Median ages at clinical and genetic diagnosis were 9.5 and 15.5 years, respectively. No significant difference in clinical presentation was observed between patients with CLDN16 and CLDN19 mutations (Table 3).

View this table:
  • View inline
  • View popup
Table 3.

Clinical characteristics of patients with CLDN16 and CLDN19 mutations

Hypomagnesemia, hypercalciuria, and nephrocalcinosis were present in all patients at diagnosis (Table 4). Hypomagnesemia and hypercalciuria were of similar severity in the two groups. In addition to nephrocalcinosis, nine patients (28%) presented nephrolithiasis. Median eGFR at diagnosis was also similar in the two groups. Most of the patients had elevated serum parathyroid hormone levels despite a moderate reduction in eGFR (Table 4). Ocular abnormalities were present at diagnosis in 21 of 23 patients (91%) with CLDN19 mutations. Ocular findings included myopia (n=14), pigmentary retinitis (n=5), macular coloboma (n=2), strabismus (n=3), astigmatism (n=2), and nystagmus (n=1). No ocular disease was found in one 10-year-old patient, and no data were available for the remaining patient with a CLDN19 mutation. No ocular abnormality was found in patients with CLDN16 mutations.

View this table:
  • View inline
  • View popup
Table 4.

Biologic characteristics of patients with CLDN16 and CLDN19 mutations

Clinical and Biologic Follow-Up

Median follow-up time since clinical diagnosis was 7.9 years (IQR=1.4–10.3) in patients with CLDN16 mutations and 3.2 years (IQR=0.3–14.5) in patients with CLDN19 mutations. Age at last follow-up was 12.4 (IQR=4.3–24.0) and 16.8 (IQR=10.5–27.9) years, respectively. Detailed follow-up information was available for 6 patients with CLDN16 mutations and 15 patients with CLDN19 mutations (Table 4).

At last follow-up, median eGFR was higher in CLDN16 patients (82 ml/min per 1.73 m2) than CLDN19 patients (51 ml/min per 1.73 m2), although this difference was not statistically significant (P=0.10). CKD, defined as an eGFR<60 ml/min per 1.73 m2 was found in 3 (33%) patients with CLDN16 mutations and 14 (61%) patients with CLDN19 mutations.

Survival analysis suggested that patients with CLDN19 mutations had a higher risk of progression to CKD and poorer renal survival than patients with CLDN16 mutations. Indeed, CKD-free survival was 100%, 100%, and 50% at 10, 20, and 30 years of age in the CLDN16 group. By contrast, CKD-free survival was 91%, 56%, and 27% at 10, 20, and 30 years of age in patients with CLDN19 mutations (Figure 3) (P<0.01). One of nine patients with CLDN16 mutations and CKD reached ESRD during follow-up at the age of 42 years; 6 of 23 patients with CLDN19 mutations presented ESRD at a median age of 25 years (IQR=20–40).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Survival without reaching CKD stage 3 by genotype.

High BP occurred in 10 patients (31%) at a median eGFR of 63 ml/min per 1.73 m2 (IQR=24–72). Mild proteinuria (median=350 mg/d, IQR=180–500) was detected in one-half of the patients for whom data were available (3 of 6 with CLDN16 and 7 of 15 with CLDN19 mutations) at a relatively late-stage CKD (median eGFR=42 ml/min per 1.73 m2). Rates of both high BP and proteinuria did not differ between the two groups.

No significant change in magnesemia and calciuria was observed between diagnosis and last follow-up in either of the two groups, and hypercalciuria persisted even at advanced stages of CKD. Patients were treated with magnesium supplements (n=16), thiazide diuretics (n=10), or indomethacine (n=7). However, urinary calcium and serum magnesium concentrations were not significantly affected by either treatment in either group.

Neurologic manifestations, mainly exercise intolerance with electromyological alteration, were present in two previously described patients (12). Electrophysiological studies were not systematically carried out for the patients without clinical manifestations. In addition, one patient presented hypomagnesemia-related seizures.

Discussion

FHHNC is a rare, genetically heterogeneous disease. Most patients described to date have mutations in the CLDN16 gene. We describe here a large cohort of patients with FHHNC mostly from France, and two-thirds had CLDN19 mutations. There were three main findings of our study: (1) FHHNC is often diagnosed late, (2) ocular impairment occurred exclusively in patients with CLDN19 mutations, and (3) patients with CLDN16 and CLDN19 mutations may have different renal prognoses, with a higher risk of CKD and ESRD in patients with CLDN19 mutations. These data contribute to improvements in the phenotypic and genotypic characterization of FHHNC.

The molecular genetic analysis detected two mutated alleles in all patients and expanded the spectrum of known disease-causing mutations of these two genes. Six different mutations of CLDN16 were detected (five missense and one nonsense); three of the missense mutations were previously unknown (p.Cys80Tyr, p.Lys183Glu, and p.Gly233Arg). These mutations affect the first and third transmembrane domains and the second extracellular loop. They result in the replacement of highly conserved amino acids and are probably pathogenic given their predicted biologic consequences (Supplemental Table 1). The haplotype and geographic origins of three families harboring the recurrent known p.Ala139Val mutation were consistent with a founder effect. For CLDN19, five of seven mutations detected were previously unknown: one missense (p.Pro28Leu affecting the first transmembrane domain), two nonsense (p.Trp18X and p.Gln57X), one frame shift (p.Thr135LeufsX9), and one large deletion (E1_E4del). All the previously described mutations of this gene were missense (5). Most of the novel mutations described here result in the production of unstable mRNAs or truncated proteins. Interestingly, the previously described p.Gly20Asp mutation was identified in 15 patients from 14 different families. All of these patients came from southwest France or Spain. The haplotype data were consistent with a founder effect, which was previously identified in Spanish families (5).

FHHNC was diagnosed on the basis of the presence of hypomagnesemia, hypercalciuria, and nephrocalcinosis in all 32 patients. Median time to diagnosis was 2.5 years, suggesting that physicians were insufficiently aware of this rare disease. FHHNC is frequently complicated by progressive renal failure. In the cohort of patients with CLDN16 mutations described in the work by Konrad et al. (2), ESRD was reported in 30% of patients at 15 years and 50% of patients at 20 years. In our study, approximately one-third of patients already had CKD at diagnosis, and more than 20% had reached ESRD at last follow-up at a median age of about 15 years, which is consistent with the findings of Konrad et al. (2). However, the risk of ESRD in patients with CLDN19 mutations was two times the risk of patients with CLDN16 mutations.

The pathogenesis of progressive renal failure in patients with FHHNC remains unclear. Progressive tubulointerstitial nephropathy is probably not directly caused by hypercalciuria and nephrocalcinosis, because no correlation was found between the degree of nephrocalcinosis and CKD progression. Interestingly, Japanese Black cattle harboring large deletions of the CLDN16 gene have chronic interstitial nephritis and CKD (15,16). In the first pathologic study of this bovine model, the work by Sasaki et al. (17) described lesions classed as “renal tubular dysplasia” with a secondary decrease in the number of nephrons. The work by Okada et al. (18) described a decrease in the number of glomeruli with immature tubules, secondary interstitial fibrosis, and lymphocytic infiltration, resulting in abnormal nephron development. Therefore, it has been suggested that defective claudin-16 function disruption may occur very early in the development of tubular tight junctions (2). Unfortunately, no equivalent data are available for humans. However, we can speculate that the early onset of ESRD may result from abnormal renal development complicated by fibrosis and nephrocalcinosis (19).

How can we account for the difference in renal outcome between patients with CLDN16 and CLDN19 mutations without differences in BP or protein excretion? The work by Konrad et al. (2) showed that some mutations of the CLDN16 gene (such as Leu151Phe) resulted in residual function, with a slower progression to renal failure. Five of six CLDN16 mutations described in this study are missense that could have a similar residual function. Concerning CLDN19 mutations, no genotype–phenotype correlation has been published. In our study, 15 of 23 patients with CLDN19 mutations had the recurrent p.Gly20Asp mutation that results in the production of a protein retained within the cell (5). Five other patients had nonsense, large deletion, or frame shift mutations. Thus, phenotype severity with higher risk of ESRD could be explained by complete loss of function mutations detected in our cohort.

Claudin-16 and -19 have also been shown to act in synergy in the reabsorption of calcium and magnesium in TAL (20,21): claudin-16 increases cation permeability, whereas claudin-19 decreases anion permeability. A direct interaction between these two proteins seems to be important for the maintenance of cation selectivity. It has been suggested that the phenotype of patients with mutated claudin-19 may result in part from the defective functioning of claudin-16 (22).

It has also been suggested that other claudins may be involved in paracellular reabsorption and regulation or interact with claudin-16 and -19. TAL also expresses claudin-3, -10b, -11, and -14, and distal tubule expresses claudin-3 and -8. Two works suggest that claudin-14 could play a role in urinary calcium excretion: in Cldn11/Cldn14 double mutant mice, a mild increase in urinary calcium and magnesium excretion was observed (23), and in Icelandic and Dutch populations, an association between two synonymous single nucleotide polymorphisms of claudin-14 gene and a higher risk to develop kidney stones and reduced bone mineral density was described (24). Nevertheless, the mechanism and the nephron segment involved in these observations have not been established. Regarding a possible interaction between claudins, in vitro studies have shown that the loss of either claudin-16 or -19 has no effect on the junctional localization of claudin-10 and -18 (21). Furthermore, phenotypic variability was recently shown in a kindred with three affected members harboring a CLDN16 mutation (25), suggesting the possible involvement of other genes or epigenetic factors.

Mutations of CLDN19 are also associated with extrarenal manifestations, such as ocular abnormalities. Several claudins are expressed in human cornea and retina (26,27). Claudin-19 is the prominent claudin expressed in fetal retinal pigment epithelium, and in minor proportion, claudin-3 is expressed; claudin-16 expression in this epithelium seems to be extremely low. Knockdown of claudin-19 by small interfering RNA abolishes the transepithelial electrical resistance, showing the importance of this protein in the permeability characteristics of this epithelium (28). Neurologic manifestations were previously described in two patients with CLDN19 mutations included in this study (12). Extrarenal symptoms may be accounted for by the expression in other tissues of claudin-19 described in the Cldn19-null mouse, which presents peripheral nervous system deficits caused by the absence of claudin-19 in the tight junction of the Schwann cells of peripheral myelinated axons (29).

Patients have been treated with thiazides and indomethacin to decrease hypercalciuria. Indomethacin decreases sodium reabsorption in the proximal tubule and may also increase the passive paracellular reabsorption of calcium (30). In this study, these treatments were found to have no effect on hypercalciuria, but data were obtained for only a limited number of patients.

The limitations of our study include its retrospective design, the multicentric nature of the population, and missing follow-up data. The relatively small population and the small number of events because of the rarity of the disease limit the power of this study to detect differences in disease expression between the two groups.

This study of 32 patients with FHHNC led to the identification of novel and recurrent mutations in the two genes known to be involved in this disease. Phenotypic analysis showed a similar clinical presentation in patients with mutations in either of these two genes except ocular abnormalities, which were found only in patients with CLDN19 mutations. The follow-up data also suggested that patients with CLDN19 mutations have a higher risk of progression to CKD and a poorer renal outcome.

Disclosures

None.

Acknowledgments

We thank the patients who participated in this study and their families for their cooperation. We thank all the physicians from the 14 French and 2 Spanish centers involved in this study and all the staff of the genetic laboratory at Georges Pompidou Hospital. We also thank the following physicians: Stéphane Decramer (CHU de Toulouse, France), Marie-Pierre Lavocat (CHU de Saint Etienne, France), Jean Sarlangue (CHU de Bordeaux, France), Alberto Vidal (CHU de Albacete, Spain), and Teresa Vendrell (Hospital Vall d’Hebron, Barcelona, Spain).

This study was made possible by funds from The French Ministry of Health (Plan Maladies Rares) and European Community FP7 EUNEFRON 201590.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.12841211/-/DCSupplemental.

  • Received December 16, 2011.
  • Accepted February 1, 2012.
  • Copyright © 2012 by the American Society of Nephrology

References

  1. ↵
    1. Michelis MF,
    2. Drash AL,
    3. Linarelli LG,
    4. De Rubertis FR,
    5. Davis BB
    : Decreased bicarbonate threshold and renal magnesium wasting in a sibship with distal renal tubular acidosis. (Evaluation of the pathophysiological role of parathyroid hormone). Metabolism 21: 905–920, 1972pmid:5071957
    OpenUrlCrossRefPubMed
  2. ↵
    1. Konrad M,
    2. Hou J,
    3. Weber S,
    4. Dötsch J,
    5. Kari JA,
    6. Seeman T,
    7. Kuwertz-Bröking E,
    8. Peco-Antic A,
    9. Tasic V,
    10. Dittrich K,
    11. Alshaya HO,
    12. von Vigier RO,
    13. Gallati S,
    14. Goodenough DA,
    15. Schaller A
    : CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 19: 171–181, 2008pmid:18003771
    OpenUrlFREE Full Text
  3. ↵
    1. Benigno V,
    2. Canonica CS,
    3. Bettinelli A,
    4. von Vigier RO,
    5. Truttmann AC,
    6. Bianchetti MG
    : Hypomagnesaemia-hypercalciuria-nephrocalcinosis: A report of nine cases and a review. Nephrol Dial Transplant 15: 605–610, 2000pmid:10809799
    OpenUrlCrossRefPubMed
  4. ↵
    1. Simon DB,
    2. Lu Y,
    3. Choate KA,
    4. Velazquez H,
    5. Al-Sabban E,
    6. Praga M,
    7. Casari G,
    8. Bettinelli A,
    9. Colussi G,
    10. Rodriguez-Soriano J,
    11. McCredie D,
    12. Milford D,
    13. Sanjad S,
    14. Lifton RP
    : Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285: 103–106, 1999pmid:10390358
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Konrad M,
    2. Schaller A,
    3. Seelow D,
    4. Pandey AV,
    5. Waldegger S,
    6. Lesslauer A,
    7. Vitzthum H,
    8. Suzuki Y,
    9. Luk JM,
    10. Becker C,
    11. Schlingmann KP,
    12. Schmid M,
    13. Rodriguez-Soriano J,
    14. Ariceta G,
    15. Cano F,
    16. Enriquez R,
    17. Juppner H,
    18. Bakkaloglu SA,
    19. Hediger MA,
    20. Gallati S,
    21. Neuhauss SC,
    22. Nurnberg P,
    23. Weber S
    : Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79: 949–957, 2006pmid:17033971
    OpenUrlCrossRefPubMed
  6. ↵
    1. Haisch L,
    2. Almeida JR,
    3. Abreu da Silva PR,
    4. Schlingmann KP,
    5. Konrad M
    : The role of tight junctions in paracellular ion transport in the renal tubule: Lessons learned from a rare inherited tubular disorder. Am J Kidney Dis 57: 320–330, 2011pmid:21186073
    OpenUrlCrossRefPubMed
  7. ↵
    1. Angelow S,
    2. Ahlstrom R,
    3. Yu AS
    : Biology of claudins. Am J Physiol Renal Physiol 295: F867–F876, 2008pmid:18480174
    OpenUrlCrossRefPubMed
  8. ↵
    1. Weber S,
    2. Schneider L,
    3. Peters M,
    4. Misselwitz J,
    5. Rönnefarth G,
    6. Böswald M,
    7. Bonzel KE,
    8. Seeman T,
    9. Suláková T,
    10. Kuwertz-Bröking E,
    11. Gregoric A,
    12. Palcoux JB,
    13. Tasic V,
    14. Manz F,
    15. Schärer K,
    16. Seyberth HW,
    17. Konrad M
    : Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 12: 1872–1881, 2001pmid:11518780
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Schwartz GJ,
    2. Muñoz A,
    3. Schneider MF,
    4. Mak RH,
    5. Kaskel F,
    6. Warady BA,
    7. Furth SL
    : New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20: 629–637, 2009pmid:19158356
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Levey AS,
    2. Coresh J,
    3. Greene T,
    4. Marsh J,
    5. Stevens LA,
    6. Kusek JW,
    7. Van Lente F,
    8. Chronic Kidney Disease Epidemiology Collaboration
    : Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766–772, 2007pmid:17332152
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Blanchard A,
    2. Jeunemaitre X,
    3. Coudol P,
    4. Dechaux M,
    5. Froissart M,
    6. May A,
    7. Demontis R,
    8. Fournier A,
    9. Paillard M,
    10. Houillier P
    : Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. Kidney Int 59: 2206–2215, 2001pmid:11380823
    OpenUrlCrossRefPubMed
  12. ↵
    1. Faguer S,
    2. Chauveau D,
    3. Cintas P,
    4. Tack I,
    5. Cointault O,
    6. Rostaing L,
    7. Vargas-Poussou R,
    8. Ribes D
    : Renal, ocular, and neuromuscular involvements in patients with CLDN19 mutations. Clin J Am Soc Nephrol 6: 355–360, 2011pmid:21030577
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Houdayer C,
    2. Gauthier-Villars M,
    3. Laugé A,
    4. Pagès-Berhouet S,
    5. Dehainault C,
    6. Caux-Moncoutier V,
    7. Karczynski P,
    8. Tosi M,
    9. Doz F,
    10. Desjardins L,
    11. Couturier J,
    12. Stoppa-Lyonnet D
    : Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat 23: 193–202, 2004pmid:14722923
    OpenUrlCrossRefPubMed
  14. ↵
    1. Vargas-Poussou R,
    2. Cochat P,
    3. Le Pottier N,
    4. Roncelin I,
    5. Liutkus A,
    6. Blanchard A,
    7. Jeunemaître X
    : Report of a family with two different hereditary diseases leading to early nephrocalcinosis. Pediatr Nephrol 23: 149–153, 2008pmid:17899212
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hirano T,
    2. Kobayashi N,
    3. Itoh T,
    4. Takasuga A,
    5. Nakamaru T,
    6. Hirotsune S,
    7. Sugimoto Y
    : Null mutation of PCLN-1/Claudin-16 results in bovine chronic interstitial nephritis. Genome Res 10: 659–663, 2000pmid:10810088
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Hirano T,
    2. Hirotsune S,
    3. Sasaki S,
    4. Kikuchi T,
    5. Sugimoto Y
    : A new deletion mutation in bovine Claudin-16 (CL-16) deficiency and diagnosis. Anim Genet 33: 118–122, 2002pmid:12047224
    OpenUrlCrossRefPubMed
  17. ↵
    1. Sasaki Y,
    2. Kitagawa H,
    3. Kitoh K,
    4. Okura Y,
    5. Suzuki K,
    6. Mizukoshi M,
    7. Ohba Y,
    8. Masegi T
    : Pathological changes of renal tubular dysplasia in Japanese black cattle. Vet Rec 150: 628–632, 2002pmid:12046787
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Okada K,
    2. Ishikawa N,
    3. Fujimori K,
    4. Goryo M,
    5. Ikeda M,
    6. Sasaki J,
    7. Watanabe D,
    8. Takasuga A,
    9. Hirano T,
    10. Sugimoto Y
    : Abnormal development of nephrons in claudin-16-defective Japanese black cattle. J Vet Med Sci 67: 171–178, 2005pmid:15750313
    OpenUrlCrossRefPubMed
  19. ↵
    1. Sugiyama A,
    2. Ozaki K,
    3. Miyazaki,
    4. Tanabe Y,
    5. Takeuchi T,
    6. Narama I
    : Renal dysplasia unrelated to claudin-16 deficiency in Japanese Black cattle. J Comp Pathol 137: 71–77, 2007pmid:17537453
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hou J,
    2. Renigunta A,
    3. Konrad M,
    4. Gomes AS,
    5. Schneeberger EE,
    6. Paul DL,
    7. Waldegger S,
    8. Goodenough DA
    : Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 118: 619–628, 2008pmid:18188451
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hou J,
    2. Renigunta A,
    3. Gomes AS,
    4. Hou M,
    5. Paul DL,
    6. Waldegger S,
    7. Goodenough DA
    : Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc Natl Acad Sci USA 106: 15350–15355, 2009pmid:19706394
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Amasheh S,
    2. Fromm M,
    3. Günzel D
    : Claudins of intestine and nephron—a correlation of molecular tight junction structure and barrier function. Acta Physiol (Oxf) 201: 133–140, 2011pmid:20518752
    OpenUrlCrossRefPubMed
  23. ↵
    1. Elkouby-Naor L,
    2. Abassi Z,
    3. Lagziel A,
    4. Gow A,
    5. Ben-Yosef T
    : Double gene deletion reveals lack of cooperation between claudin 11 and claudin 14 tight junction proteins. Cell Tissue Res 333: 427–438, 2008pmid:18663477
    OpenUrlCrossRefPubMed
  24. ↵
    1. Thorleifsson G,
    2. Holm H,
    3. Edvardsson V,
    4. Walters GB,
    5. Styrkarsdottir U,
    6. Gudbjartsson DF,
    7. Sulem P,
    8. Halldorsson BV,
    9. de Vegt F,
    10. d’Ancona FC,
    11. den Heijer M,
    12. Franzson L,
    13. Christiansen C,
    14. Alexandersen P,
    15. Rafnar T,
    16. Kristjansson K,
    17. Sigurdsson G,
    18. Kiemeney LA,
    19. Bodvarsson M,
    20. Indridason OS,
    21. Palsson R,
    22. Kong A,
    23. Thorsteinsdottir U,
    24. Stefansson K
    : Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41: 926–930, 2009pmid:19561606
    OpenUrlCrossRefPubMed
  25. ↵
    1. Seeley HH,
    2. Loomba-Albrecht LA,
    3. Nagel M,
    4. Butani L,
    5. Bremer AA
    : Familial hypomagnesemia with hypercalciuria and nephrocalcinosis in three siblings having the same genetic lesion but different clinical presentations [published online ahead of print June 1, 2011]. World J Pediatr doi:10.1007/s12519-011-0295-3
  26. ↵
    1. Ban Y,
    2. Dota A,
    3. Cooper LJ,
    4. Fullwood NJ,
    5. Nakamura T,
    6. Tsuzuki M,
    7. Mochida C,
    8. Kinoshita S
    : Tight junction-related protein expression and distribution in human corneal epithelium. Exp Eye Res 76: 663–669, 2003pmid:12742348
    OpenUrlCrossRefPubMed
  27. ↵
    1. Rizzolo LJ,
    2. Peng S,
    3. Luo Y,
    4. Xiao W
    : Integration of tight junctions and claudins with the barrier functions of the retinal pigment epithelium. Prog Retin Eye Res 30: 296–323, 2011pmid:21704180
    OpenUrlCrossRefPubMed
  28. ↵
    1. Peng S,
    2. Rao VS,
    3. Adelman RA,
    4. Rizzolo LJ
    : Claudin-19 and the barrier properties of the human retinal pigment epithelium. Invest Ophthalmol Vis Sci 52: 1392–1403, 2011pmid:21071746
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Miyamoto T,
    2. Morita K,
    3. Takemoto D,
    4. Takeuchi K,
    5. Kitano Y,
    6. Miyakawa T,
    7. Nakayama K,
    8. Okamura Y,
    9. Sasaki H,
    10. Miyachi Y,
    11. Furuse M,
    12. Tsukita S
    : Tight junctions in Schwann cells of peripheral myelinated axons: A lesson from claudin-19-deficient mice. J Cell Biol 169: 527–538, 2005pmid:15883201
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Monnens L,
    2. Starremans P,
    3. Bindels R
    : Great strides in the understanding of renal magnesium and calcium reabsorption. Nephrol Dial Transplant 15: 568–571, 2000pmid:10809791
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 7 (5)
Clinical Journal of the American Society of Nephrology
Vol. 7, Issue 5
May 07, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis: Phenotype–Genotype Correlation and Outcome in 32 Patients with CLDN16 or CLDN19 Mutations
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis: Phenotype–Genotype Correlation and Outcome in 32 Patients with CLDN16 or CLDN19 Mutations
Astrid Godron, Jérôme Harambat, Valérie Boccio, Anne Mensire, Adrien May, Claire Rigothier, Lionel Couzi, Benoit Barrou, Michel Godin, Dominique Chauveau, Stanislas Faguer, Marion Vallet, Pierre Cochat, Philippe Eckart, Geneviève Guest, Vincent Guigonis, Pascal Houillier, Anne Blanchard, Xavier Jeunemaitre, Rosa Vargas-Poussou
CJASN May 2012, 7 (5) 801-809; DOI: 10.2215/CJN.12841211

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis: Phenotype–Genotype Correlation and Outcome in 32 Patients with CLDN16 or CLDN19 Mutations
Astrid Godron, Jérôme Harambat, Valérie Boccio, Anne Mensire, Adrien May, Claire Rigothier, Lionel Couzi, Benoit Barrou, Michel Godin, Dominique Chauveau, Stanislas Faguer, Marion Vallet, Pierre Cochat, Philippe Eckart, Geneviève Guest, Vincent Guigonis, Pascal Houillier, Anne Blanchard, Xavier Jeunemaitre, Rosa Vargas-Poussou
CJASN May 2012, 7 (5) 801-809; DOI: 10.2215/CJN.12841211
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Summary
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Incidence and Risk Factors for Dialysis Reinitiation among Patients with a History of Dialysis Dependency
  • Survey of Salary and Job Satisfaction of Transplant Nephrologists in the United States
  • Implications of Accumulated Cold Time for US Kidney Transplantation Offer Acceptance
Show more Original Articles

Genetics

  • GWAS of Hematuria
  • APOL1 Kidney Risk Variants and Proteomics
  • Exome Chip Analyses and Genetic Risk for IgA Nephropathy among Han Chinese
Show more Genetics

Cited By...

  • Amelogenesis imperfecta in familial hypomagnesaemia and hypercalciuria with nephrocalcinosis caused by CLDN19 gene mutations
  • Working Out Nephronophthisis Genetics One Family at a Time
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire